Review: Peroxisome Proliferator-Activated Receptor-γ and Its Role in the Development and Treatment of Diabetes

por Leff, Todd, Mathews, Suresh T., Camp, Heidi S.
Publicado 2004

Thiazolidinediones and insulin resistance: Peroxisome proliferatoractivated receptor γ activation stimulates expression of the CAP gene

por Ribon, Vered, Johnson, John H., Camp, Heidi S., Saltiel, Alan R.
Publicado 1998

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection

por Mohamed, Mohamed‐Eslam F., Klünder, Ben, Camp, Heidi S., Othman, Ahmed A.
Publicado en Clin Pharmacol Ther (2019)

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib

por Mohamed, Mohamed‐Eslam F., Beck, Denise, Camp, Heidi S., Othman, Ahmed A.
Publicado en J Clin Pharmacol (2019)

PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis

por Ren, Delin, Collingwood, Trevor N., Rebar, Edward J., Wolffe, Alan P., Camp, Heidi S.
Publicado 2002

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: resul...

por Strand, Vibeke, Pope, Janet, Tundia, Namita, Friedman, Alan, Camp, Heidi S., Pangan, Aileen, Ganguli, Arijit, Fuldeore, Mahesh, Goldschmidt, Debbie, Schiff, Michael
Publicado en Arthritis Res Ther (2019)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumat...

por Strand, Vibeke, Pope, Janet, Tundia, Namita, Friedman, Alan, Camp, Heidi S., Pangan, Aileen, Ganguli, Arijit, Fuldeore, Mahesh, Goldschmidt, Debbie, Schiff, Michael
Publicado en Arthritis Res Ther (2020)

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy

por Kremer, Joel M., Emery, Paul, Camp, Heidi S., Friedman, Alan, Wang, Li, Othman, Ahmed A., Khan, Nasser, Pangan, Aileen L., Jungerwirth, Steven, Keystone, Edward C.
Publicado en Arthritis Rheumatol (2016)

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

por Genovese, Mark C., Smolen, Josef S., Weinblatt, Michael E., Burmester, Gerd R., Meerwein, Sebastian, Camp, Heidi S., Wang, Li, Othman, Ahmed A., Khan, Nasser, Pangan, Aileen L., Jungerwirth, Steven
Publicado en Arthritis Rheumatol (2016)

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

por Parmentier, Julie M., Voss, Jeff, Graff, Candace, Schwartz, Annette, Argiriadi, Maria, Friedman, Michael, Camp, Heidi S., Padley, Robert J., George, Jonathan S., Hyland, Deborah, Rosebraugh, Matthew, Wishart, Neil, Olson, Lisa, Long, Andrew J.
Publicado en BMC Rheumatol (2018)

Reduced heart size and increased myocardial fuel substrate oxidation in ACC2 mutant mice

por Essop, M. Faadiel, Camp, Heidi S., Choi, Cheol Soo, Sharma, Saumya, Fryer, Ryan M., Reinhart, Glenn A., Guthrie, Patrick H., Bentebibel, Assia, Gu, Zeiwei, Shulman, Gerald I., Taegtmeyer, Heinrich, Wakil, Salih J., Abu-Elheiga, Lutfi
Publicado 2008